From ClinicalTrials.gov
GLP-1 clinical trial results
290 Phase 3 trials with posted results, 146 of them named. Each page shows the results and side effects arm by arm, as the registry posts them. The newest update at source is Nov 4, 2026.
Largest first
Tirzepatide trials with results
21 trials, 14,528 participants.
| Trial | Medication | People | Primary result |
|---|---|---|---|
| SURMOUNT-1A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight | Tirzepatide | 2,539 | Percent Change From Baseline in Body Weight (Primary Treatment Period) (percent change), Baseline, Week 72. Placebo: -2.4; 5 mg Tirzepatide: -16.0; 10 mg Tirzepatide: -21.4; 15 mg Tirzepatide: -22.5. |
| SURPASS-4A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk | Tirzepatide | 2,002 | Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg) (Percentage of HbA1c), Baseline, Week 52. 10 mg Tirzepatide: -2.43; 15 mg Tirzepatide: -2.58; Insulin Glargine: -1.44. |
| SURPASS-3A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes | Tirzepatide | 1,444 | Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg) (Percentage of HbA1c), Baseline, Week 52. 10 mg Tirzepatide: -2.20; 15 mg Tirzepatide: -2.37; Insulin Degludec: -1.34. |
| SURPASS-6A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin | Tirzepatide | 1,428 | Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses of Tirzepatide 5 mg, 10 mg and 15 mg) (Percentage of HbA1c), Baseline, Week 52. Pooled 5 mg/10 mg/15 mg Tirzepatide: -2.26; Insulin Lispro: -1.16. |
| SURMOUNT-2A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight | Tirzepatide | 938 | Percent Change From Baseline in Body Weight (percent change), Baseline, Week 72. Placebo: -3.3; 10 mg Tirzepatide: -13.4; 15 mg Tirzepatide: -15.7. |
| NCT04093752A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo) | Tirzepatide | 917 | Mean Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg) (Percentage of HbA1c), Baseline, Week 40. 10 mg Tirzepatide: -2.44; 15 mg Tirzepatide: -2.49; Insulin Glargine: -0.95. |
| SURMOUNT-4A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss | Tirzepatide | 783 | Percent Change From Randomization in Body Weight at Week 88 (percent change), Randomization (Week 36), Week 88. Placebo: 14.8; Tirzepatide MTD: -6.7. |
| NCT04847557A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial | Tirzepatide | 731 | Change From Baseline in the Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS) (Score on a scale), Baseline, Week 52. Tirzepatide - MTD: 19.51; Placebo: 12.68. |
| SURMOUNT-3A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program | Tirzepatide | 579 | Percent Change From Baseline in Body Weight (Percent change), Baseline, 72 Weeks. Placebo: 3.3; Tirzepatide: -21.1. |
| SURPASS-1A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone | Tirzepatide | 478 | Change From Baseline in Hemoglobin A1c (HbA1c) (Percentage of HbA1c), Baseline, Week 40. 5 mg Tirzepatide: -1.87; 10 mg Tirzepatide: -1.89; 15 mg Tirzepatide: -2.07; Placebo: 0.04. |
| SURPASS-5A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin | Tirzepatide | 475 | Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg) (Percentage of HbA1c), Baseline, Week 40. 10 mg Tirzepatide: -2.59; 15 mg Tirzepatide: -2.59; Placebo: -0.93. |
| SURMOUNT-OSAObstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea | Tirzepatide | 469 | Change From Baseline in Apnea-Hypopnea Index (AHI) (events per hour), Baseline, Week 52. Tirzepatide MTD_GPI1: -25.25; Placebo_GPI1: -5.25; Tirzepatide MTD_GPI2: -29.27; Placebo_GPI2: -5.51. |
| NCT03861039A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes | Tirzepatide | 443 | Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration (Participants), Baseline through Week 52. 5 mg Tirzepatide: 0; 10 mg Tirzepatide: 1; 15 mg Tirzepatide: 1. |
| SURMOUNT-JA Study of Tirzepatide (LY3298176) in Participants With Obesity Disease | Tirzepatide | 267 | Mean Percent Change in Body Weight (Percent change), Baseline, 72 Weeks. 10 mg Tirzepatide: -17.8; 15 mg Tirzepatide: -22.7; Placebo: -1.7. |
| SURPASS-CN-INSA Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes | Tirzepatide | 257 | Mean Change From Baseline in HbA1c (Tirzepatide 10 or 15 Milligram [mg]) (millimoles per mole (mmol/mol)), Baseline, Week 40. 10 mg Tirzepatide: -26.1; 15 mg Tirzepatide: -25.9; Placebo: -9.96. |
| SURMOUNT-CNA Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN) | Tirzepatide | 210 | Mean Percent Change From Baseline in Body Weight (Percent change), Baseline, Week 52. 10 mg Tirzepatide: -14.4; 15 mg Tirzepatide: -19.9; Placebo: -2.4. |
| NCT05963022A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO) | Tirzepatide | 206 | Change From Baseline in Hemoglobin A1c (HbA1c) (percentage of HbA1c), Baseline, Week 40. 5 mg Tirzepatide: -2.19; 10 mg Tirzepatide: -1.75; 15 mg Tirzepatide: -2.03; Placebo: -0.77. |
| SYNERGY-NASHA Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH) | Tirzepatide | 190 | Percentage of Participants With Absence of Nonalcoholic Steatohepatitis (NASH) With no Worsening of Fibrosis on Liver Histology (Percentage of participants), Week 52. 5 mg Tirzepatide: 51.84; 10 mg Tirzepatide: 63.13; 15 mg Tirzepatide: 73.92; Placebo: 12.62. |
| SURPASS-PEDSA Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both | Tirzepatide | 99 | Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses of Tirzepatide 5 mg and 10 mg) (percentage of HbA1c), Baseline, Week 30. Pooled Doses of Tirzepatide (5 mg, 10 mg): -2.03; Placebo: -0.23. |
| NCT03482024A Study of Tirzepatide (LY3298176) in Participants With Impaired Kidney Function | Tirzepatide | 45 | Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Tirzepatide From Time Zero to Tlast (AUC[0-tlast]) (Nanogram*hour per Millilitre (ng*h/mL)), Predose, 8hours(h), 12h, 24h, 48h, 72h, 96h, 168h, 336h postdose. Tirzepatide - Control: 78400; Tirzepatide - Mild Renal Impairment: 81900; Tirzepatide - Moderate Renal Impairment: 98300; Tirzepatide - Severe Renal Impairment: 81200; Tirzepatide - End Stage Renal Disease (ESRD): 88500. |
| NCT05696847A Study of Tirzepatide (LY3298176) in Pediatric Participants With Obesity | Tirzepatide | 28 | See the trial's page: several measures or groups. |
Updated automatically
What just changed in the registry
- TrialNew Semaglutide study registered: A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obesity
- TrialSemaglutide study now completed (was unknown): The Effect of Different Diets on Arterial Stiffness in Obese Patients on Semaglutide
- TrialSemaglutide study now recruiting (was not yet recruiting): Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use Outcomes
- TrialExenatide study now completed (was active, not recruiting): Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol
- TrialTirzepatide study now recruiting (was not yet recruiting): AI-Assisted Lifestyle Intervention Versus Tirzepatide for Obesity and Newly Diagnosed Type 2 Diabetes
- TrialTirzepatide study now recruiting (was not yet recruiting): A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes
- TrialNew Liraglutide study registered: The Effect of Liraglutide on Body Weight, Body Composition, Ectopic Lipid Accumulation and Insulin Sensitivity in Subjects With Overweight or Obesity Without Diabetes
- TrialNew MariTide study registered: Comparing the Extent to Which Maridebart Cafraglutide is Made Available in the Body of Participants Living With Overweight or Obesity After Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA)
Written from each source's own record as it changes. Every change on GLPcompare
GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.